182 results about "Peripheral blood cell" patented technology

Methods and compositions relating to the production of induced pluripotent stem cells (iPS cells) are disclosed. For example, induced pluripotent stem cells may be generated from peripheral blood cells, such as human blood progenitor cells, using episomal reprogramming and feeder-free or xeno-free conditions. In certain embodiments, the invention provides novel methods for improving overall reprogramming efficiency with low number of blood progenitor cells.

The invention belongs to the field of medical image processing, and relates to a five-classification technology for leukocytes in a human peripheral blood cell image, particularly to a leukocyte five-classification method based on deep learning. According to the leukocyte five-classification method, leukocytes are detected from a microscope image by using simple color-component relationships and morphological operations, basophils and eosinophils are identified by using particle characteristics and SVM, the remaining cell image characteristics are automatically extracted by using a convolutional neural network, and finally the remaining three-classification is achieved by using random forest. With the leukocyte five-classification method of the present invention, the errors caused by segmentation in the traditional method can be avoided, the leukocyte five-classification problem can be effectively solved, and the cells in different databases can achieve the good classification results.

A method of diagnosing Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) is disclosed which was identified by the fact that an increased level of iron regulating protein-2 (IRP-2) was identified in Alzheimer's patients. Further, diseases of increased cellular metabolism such as cancer showed high levels of both IRP-2 and transferrin receptor. This suggests that, in diseases of increased cellular metabolism, both aspects of iron accumulation are highly expressed, while in Alzheimer's disease only IRP-2 is highly expressed. From these results, a non-invasive test for Alzheimer's disease may be produced using patient samples containing peripheral blood cells and identifying the level of expression of IRP-2 and Transferrin receptor. Those patients which: 1. over-express IRP-2 as compared with normal controls, and 2. have comparable levels of Transferrin receptor expression to normal controls, can be identified as having or prone to AD and MCI. Further, it can be envisioned that this may be used for further diagnosis and staging of cancers of the blood.

Disclosed are methods to diagnose a patient that has a pulmonary disease, and particularly, pulmonary arterial hypertension, using biomarkers that are differentially regulated in the peripheral blood cells of patients with such disease as compared to individuals that do not have the disease. Also disclosed are methods to diagnose a patient that has idiopathic pulmonary arterial hypertension as compared to pulmonary arterial hypertension associated with secondary causes. Pluralities of nucleotides and antibodies useful in the invention are described. Methods of identifying compounds with the potential to treat pulmonary arterial hypertension (PAH) are also described.

Intravenous administration of bone marrow cells collected from rat bone marrow to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

Intravenous administration of bone marrow cells collected from rat bone marrow or peripheral blood to a rat cerebral infarction model was found to be effective in treating cerebral infarction. Human and murine bone marrow stem cells showed similar effects. Mesenchymal cells such as bone marrow cells, cord blood cells, or peripheral blood cells can be used as agents for in vivo administration against cranial nerve diseases.

The invention relates to a kit for processing human marrow, cord blood and peripheral blood stem cells and a stem cell processing method. The kit radically solves the problems of high manufacture cost, low cell activity, indefinite reaction of markers in a human body, mobilizing agent injection causing patient pain, long obtainment time, complication, clinical unsuitability, and the like in the prior cell separation technology. The invention has the technical scheme that the kit comprises the following three reagents: (1) a diluent comprising 0.9 percent of sodium chloride injection or PBS solution, (2) a precipitator comprising 6 percent of hydroxyethyl starch or 0.2-1 percent of methyl cellulose and (3) a separating solution which has the density of 1.074-1.076 and is prepared by saccharosan and diatrizoate. The kit is easy to store and transport and convenient and rapid to use and can be produced in industrialization.

Hyaluronic Acid (HA) is an essential component of tissue extracellular matrices that contributes to the architecture of stem cell niches, which determine the fate of stem cells. Decreased levels of HA are found in subjects experiencing a variety of pathological conditions, as well as in subjects receiving a variety of therapeutic interventions, for example, chemotherapy or radiotherapy, to treat pathological conditions. The use of HA to reconstitute a tissue extracellular matrix partially or completely depleted of HA is described. More particularly, described herein is the use of exogenous forms of HA as an adjuvant in the restoration of the local tissue specific stem cell microenvironment to enhance stem cell recovery or engraftment and thus tissue recovery and remodeling following stem cell transplantation or other therapies. The effect of HA on hematopoietic stem cells is illustrative of the invention. Mice having severe bone marrow hypoplasia, and pancytopenia resulting from treatment with 5-fluorouracil recovered more rapidly if treated with HA. Similarly, mice transplanted with hematopoietic stem cells following lethal irradiation exhibited enhanced recovery of peripheral blood cell counts when treated with HA as an adjuvant therapy compared to control mice transplanted with hematopoietic stem cells without adjuvant therapy.

The invention discloses a method for detecting anti-CD19 chimeric antigen receptor T cell effects of inhibiting leukemia cells. The method comprises 1, mixing anti-CD19 chimeric antigen receptor T cells and leukemia cells according to a certain ratio, and transplanting the mixed cells into an immunodeficient mouse model, wherein the anti-CD19 chimeric antigen receptor T cell has an accession number of CCTCC NO: C201503, 2, carrying out immunodeficient mouse model peripheral blood cell dyeing, and 3, detecting the dyed peripheral blood cells by a flow cytometer. Human leukemia cells and leukemia cell inhibition cells are transplanted into an immunodeficient mouse model together so that effects of inhibiting different human leukemia cells can be really shown and high effectiveness and accuracy of the inhibition effect detection method are guaranteed.

Methods and kits are provided for assessing radiation injury and exposure in a subject. The methods comprise measuring the levels of at least two (2) protein biomarkers from different biological pathways and correlating the levels with an assessment of radiation injury and exposure. Additional use of peripheral blood cell counts and serum enzyme biomarkers, evaluated in the early time frame after a suspected radiation exposure, and use of integrated multiple parameter triage tools to enhance radiation exposure discrimination and assessment are also provided. The information obtained from such methods can be used by a clinician to accurately assess the extent of radiation injury/exposure in the subject, and thus will provide a valuable tool for determining treatment protocols on a subject by subject basis.

The present invention provides an isolated myeloid-like cell population comprising a majority of cells that are lineage negative, and which express both CD44 antigen, CD11b antigen, and hypoxia inducible factor 1α (HIF-1α). These cells have beneficial vasculotrophic and neurotrophic activity when intraocularly administered to the eye of a mammal, particularly a mammal suffering from an ocular degenerative disease. The myeloid-like cells are isolated by treating bone marrow cells, peripheral blood cells or umbilical cord cells with an antibody against CD44 (hyaluronic acid receptor), against CD11b, CD14, CD33, or against a combination thereof and using flow cytometry to positively select CD44 and/or CD11b expressing cells therefrom. The isolated myeloid-like bone marrow cells of the invention can be transfected with a gene encoding a therapeutically useful protein, for delivering the gene to the retina.

The present invention is directed to the TVEMF-expansion of mammalian peripheral blood stem cells, preferably CD34+/CD38− cells, to compositions resulting from the TVEMF-expanded cells, and to a method of treating disease or repairing tissue with the compositions.

A method of diagnosing cancer or a pre-malignant lesion is disclosed. The method comprises determining a level of CD24 expressed on peripheral blood cells of a subject in need thereof, wherein the level of CD24 above a predetermined threshold is indicative of the cancer or the pre-malignant lesion.

The invention relates to a human marrow, cord blood or peripheral blood stem cell treating kit and a stem cell separating method. The kit consists of liquid 1, liquid 2 and liquid 3. Based on the prior art, brain protein hydrolysate is added into the liquid 1, so that the stem cells recovery quantity of the treating sample is effectively improved. The kit is used for separating the human marrow from the cord blood or the peripheral blood. Aiming at a cord blood sample, the separated cell recovery sum is improved by 5.9-15.8%, and the separated CD34 stem cell recovery sum is improved by 5.0-8.8%; aiming at a marrow sample, the separated cell recovery sum is improved by 8.7-21%, and the separated CD34 stem cell recovery sum is improved by 8.4-11%; and aiming at a peripheral blood sample, the separated cell recovery sum is improved by 23.1-46.7%, and the separated CD34 stem cells recovery sum is improved by 10.8-25.6%. Due to the improvement of the target stem cells separating and recovering ratio, the human marrow samples, cord blood samples or peripheral blood stem cell samples can be effectively saved, and the use efficiency of the samples can be improved.

Disclosed and claimed are methods for the isolation and use of stem cell modulating factors for regulating stem cell cycle and for accelerating the post-chemotherapy peripheral blood cell recovery. Also disclosed and claimed are the inhibitors and stimulators of stem cell proliferation.

The invention discloses a method for detecting PAH (Polycyclic Aromatic Hydrocarbon) gene mutation by utilizing a high-resolution melting curve analysis technique. The method is characterized by comprising the following steps: adopting a silica gel adsorption method to extract the genome DNA of an oral epithelial cell/peripheral blood cell sample of a detected person, designing the third, sixth, seventh, eleventh and twelfth exon sequences of the PAH gene as detection primers of a template, and carrying out mutation detection on the gene sequences after PCR (Polymerase Chain Reaction) amplification according to the high-resolution melting curve analysis technique. The method has the advantages of high sensitivity, good specificity and high detection speed and can quickly screen common mutation sites of phenylalanine hydroxylase genes. The invention provides a new basis for the method for detecting PAH gene mutation.

The invention belongs to the field of biomedicine, and provides a detection kit and a detection method for methylation of septin9 gene in human peripheral blood cell-free DNA. The kit comprises a primer sequence corresponding to a septin9 gene methylation detection site, a septin9 gene detection site probe sequence, a primer sequence corresponding to a reference gene detection site, and a reference gene detection site probe sequence, wherein the septin9 gene detection site is one site of septin9 gene CpG island 3, and the reference gene is Actin. The design and result reading of the detection kit provided by the invention are simple and convenient in the whole detection flow, and the detection result is reliable and high in specificity and sensitivity. By carrying out enzymolysis of cell-free DNA for detection of methylation of the septin9 gene, the sample loss is small. The method is simple, quick, economical and practical. The detection kit and detection method can be used for assisting in screening and diagnosis of carcinoma of large intestine, and further improving the cure rate and lowering death rate.

The invention discloses a cultivation method of a gynogenesis megalobrama amblycephala, which comprises the following steps of: firstly selecting and breeding a female megalobrama amblycephala and a male erythroculter ilishaeformis bleeker as parent fishes; then carrying out artificial induced spawning to obtain the sperms of the erythroculter ilishaeformis bleeker and the ripe ovums of the megalobrama amblycephala; mixing the erythroculter ilishaeformis bleeker sperms inactivated by ultraviolet rays with the ripe ovums of the megalobrama amblycephala; 3-4 minutes later, placing the ovums activated at 0-4 DEG C for cold shock treatment for 20-30 minutes; and after incubating embryos treated by cold shock at 23-24 DEG C, obtaining diploid gynogenesis megalobrama amblycephalas through a flow type cell DNA content determination method and a chromosome ploidy detection method of peripheral blood cell culturing. The cultivation method of the gynogenesis megalobrama amblycephala has the advantages of short cultivation time, fast growth speed, high incubation rate, excellent offspring property, and the like, and has great importance on aspects of fish inheritance breeding and biological evolution researches.